ongoing trials - trial from www.clinicaltrials.gov

Study With Phage for CF Subjects With Pseudomonas Lung Infection

Code: NCT06998043 **Year:** 2025 **Date:** **Author:**

Study design (if review, criteria of inclusion for studies)

Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT

Participants

ADULT, OLDER_ADULT

Interventions

BIOLOGICAL: BX004|OTHER: Placebo

Outcome measures

Change in sputum Pseudomonas aeruginosa (PsA) burden at 8 weeks (EOT), Change from baseline in PsA colony-forming units (CFU) per g of sputum, 8 weeks

Keywords

Phage therapy; Anti-bacterial agents; pharmacological_intervention; Bacterial Infections; Infection; Inhalation OR nebulised; Pseudomonas aeruginosa; Pseudomonas; Respiratory Tract Diseases; Respiratory Tract Infections;